Solid tumor

There are 157 papers on solid tumor in aging research: 12 trials and 76 observational studies in people, 25 in animals, 1 in cells, 38 reviews. The newest story, Nov 12, 2026: “Later Hodgkin lymphoma treatment linked to lower solid cancer risk”.

Disease

157 papers study it129 more mention it15 findings

19 new papers in 30 daysSee all 286 papers on solid tumor

“Truncating mutations accounted for 34.2% of solid but 24.4% of hematologic alterations”
One Gene, Two States: Truncating Loss Versus Retained Full-Length p53 in Solid and Hematologic CancersInternational journal of molecular sciences2026doi:10.3390/ijms272110024
  • Human trial12
  • Humans76
  • Animals25
  • Cells1
  • In silico4

Interventions

2

Stnig

downin mice1

1 study
  1. Stnig decreases solid tumor in mice with senescence-inducing chemotherapy.

    Animalswith senescence-inducing chemotherapy

More on Stnig

Radiation

no changein humans1

1 study
  1. Radiation was not clearly linked with solid tumor in humans (prolonged occupational exposure) (ERR per 100 mGy 0.01 (-0.03; 0.05)).

    Humansprolonged occupational exposurechronic low-dose gamma radiation30.2 y follow-upn = 135,193

More on Radiation

Upstream

1

TP53

no changein humans1

1 study
  1. TP53 was not clearly linked with solid tumor in humans (classic LFS alleles at high variant allele fraction).

    Humansclassic LFS alleles at high variant allele fraction

    Cancer risk from one gene appeared mainly acquired in midlife

    American journal of human genetics

More on TP53

Associations

11

Clonal hematopoiesis of indeterminate potential

upin humans2HR 1.13

2 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with solid tumor in humans (UK Biobank participants without pre-baseline cancer) (HR 1.13, 95% CI 1.08–1.19).

    HumansUK Biobank participants without pre-baseline cancer

    Blood-cell mutations linked to two solid cancer subtypes

    medRxivPreprint
  2. Solid tumor is associated with clonal hematopoiesis of indeterminate potential in solid tumor patients versus normal individuals.

    Reviewin solid tumor patients versus normal individuals

More on Clonal hematopoiesis of indeterminate potential

More recent treatment era

downin humans1−25% lower risk

1 study
  1. more recent treatment era is associated with solid tumor in humans (25% lower risk).

    HumansTreatment in 2000–2010 compared with 1954–1989; decrease attenuated and nonsignificant after radiotherapy adjustmentfemales

    Later Hodgkin lymphoma treatment linked to lower solid cancer risk

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Radiotherapy

upin humans1

1 study
  1. Radiotherapy is associated with solid tumor in humans (Hodgkin lymphoma survivors).

    HumansHodgkin lymphoma survivorsfemales

    Later Hodgkin lymphoma treatment linked to lower solid cancer risk

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

More on Radiotherapy

Truncating TP53 mutations

upin humans1

1 study
  1. Solid tumor is associated with truncating TP53 mutations in humans (solid tumors compared with hematologic malignancies) (34.2% versus 24.4%; χ2 = 33.7, p = 2.3 × 10−7).

    Humanssolid tumors compared with hematologic malignancies

    Solid and blood cancers differ in how one gene is altered

    International journal of molecular sciences

More on Truncating TP53 mutations

Circulating tumor-associated cells

upin humans1+89% sensitivity

1 study
  1. Solid tumor is associated with circulating tumor-associated cells in therapy-naive stage I/II cancers (88.65% sensitivity).

    Humansin therapy-naive stage I/II cancers

More on Circulating tumor-associated cells

Autosomal-recessive/X-linked telomere biology disorder genotype

upin humans1

1 study
  1. Autosomal-recessive/X-linked telomere biology disorder genotype is linked with a higher risk of solid tumor in humans (AR/XLR inheritance) (O:E 23.97 [95% CI, 10.96-45.50]).

    HumansAR/XLR inheritance

DKC1

upin humans1

1 study
  1. DKC1 is associated with solid tumor in humans (germline DKC1 mutation carriers) (nearly all solid tumors; solid tumors 2.8% overall).

    Humansgermline DKC1 mutation carriersmales

More on DKC1

Muscle strength

upin humans1

1 study
  1. Solid tumor is associated with muscle strength in humans (Compared with patients with chronic heart failure).

    HumansCompared with patients with chronic heart failure

Body mass index

downin humans1

1 study
  1. Solid tumor is associated with body mass index in humans (Compared with patients with chronic heart failure).

    HumansCompared with patients with chronic heart failure

Gamma radiation

upin mice1

1 study
  1. Gamma radiation raises the risk of solid tumor in mice (ERR 0.45).

    Animals0.10 Gyfemales

More on Gamma radiation

All 11

Trial sponsors

Funding

6 grants since 2018

National Cancer Institute$674KJapan Society for the Promotion of Science¥17.4M

Latest

Dec 2025: 6Jan 2026: 13Feb 2026: 11Mar 2026: 14Apr 2026: 3May 2026: 4Jun 2026: 10Jul 2026: 8Aug 2026: 13Sep 2026: 4Oct 2026: 8Nov 2026: 12106 papers in 12 months
Journal of Clinical Oncology

Later Hodgkin lymphoma treatment linked to lower solid cancer risk

Among female Hodgkin lymphoma survivors, treatment in 2000–2010 was associated with a 25% lower relative risk of solid cancers than treatment in 1954–1989.Among female Hodgkin lymphoma survivors, treatment in 2000–2010 was associated with a 25% lower relative risk of solid cancers than treatment in 1954–1989.

Cohort · 7,428 peoplePopulations
International Journal of Molecular Sciences

Solid and blood cancers differ in how one gene is altered

Protein-shortening mutations accounted for 34.2% of samples with the altered gene in solid cancers, versus 24.4% in blood cancers.Protein-shortening mutations accounted for 34.2% of samples with the altered gene in solid cancers, versus 24.4% in blood cancers.

Meta-analysisMechanisms
medRxiv

Blood-cell mutations linked to two solid cancer subtypes

Solid cancer risk was higher in people with groups of mutated blood cells than in people without them, with a hazard ratio of 1.13.Solid cancer risk was higher in people with groups of mutated blood cells than in people without them, with a hazard ratio of 1.13.

Preprint: cohort studyCancer

See all 286 papers on solid tumor